LOMECEL-B boosts 6MWT by 63m at 9 months in Phase 2b frailty trial.
Simantini Singh Deo
FDA accepts Opus sNDA for phentolamine 0.75% in presbyopia.
Simantini Singh Deo
Japan grants orphan status to rilzabrutinib for IgG4-RD.
Simantini Singh Deo
SEP-631 shows strong Phase 1 data; Phase 2b planned in CSU.
Simantini Singh Deo